Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and the estrogen effect on endothelial cells

[1]  A. Haeberli,et al.  Effects of low and high dose oral contraceptives on blood coagulation and thrombogenesis induced by vascular subendothelium exposed to flowing human blood. , 1991, Contraception.

[2]  J. Jespersen,et al.  Enhanced generation and resolution of fibrin in women above the age of 30 years using oral contraceptives low in estrogen , 1991 .

[3]  P. Valent,et al.  Interleukin-4 counteracts pyrogen-induced downregulation of thrombomodulin in cultured human vascular endothelial cells. , 1991, Blood.

[4]  J. David,et al.  Hemostasis profile in women taking low‐dose oral contraceptives , 1991, American journal of obstetrics and gynecology.

[5]  P. Bosma,et al.  Studies on the mechanism of action of oral contraceptives with regard to fibrinolytic variables. , 1990, American journal of obstetrics and gynecology.

[6]  J. Jespersen,et al.  Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid. , 1990, American journal of obstetrics and gynecology.

[7]  R. Abbate,et al.  Effects of long-term gestodene-containing oral contraceptive administration on hemostasis. , 1990, American journal of obstetrics and gynecology.

[8]  C. Kelleher.  Clinical aspects of the relationship between oral contraceptives and abnormalities of the hemostatic system: relation to the development of cardiovascular disease. , 1990, American journal of obstetrics and gynecology.

[9]  P. Fioretti,et al.  Oral contraceptives and venous thromboembolic disease: the effect of the oestrogen dose. , 1988, Maturitas.

[10]  A. Haeberli,et al.  Excessive Deposition of Fibrin, Platelets and Platelet Thrombi on Vascular Subendothelium During Contraceptive Drug Treatment , 1987, Thrombosis and Haemostasis.

[11]  R. Bertina,et al.  Effects of two low-dose oral contraceptives on circulating components of the coagulation and fibrinolytic systems. , 1987, The Journal of laboratory and clinical medicine.

[12]  K. Bauer,et al.  Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency. , 1985, The Journal of clinical investigation.

[13]  R. Kirsch,et al.  Fibrinogen and fibrinogen-related peptides in cancer , 1984 .

[14]  M A Shifman,et al.  The in vivo metabolism of antithrombin III and antithrombin III complexes. , 1982, The Journal of biological chemistry.

[15]  E. Mammen,et al.  Oral contraceptives and blood coagulation: a critical review. , 1982, American journal of obstetrics and gynecology.

[16]  Stadel Bv.  Oral contraceptives and cardiovascular disease. (Second of two parts). , 1981 .

[17]  B. Stadel.  Oral contraceptives and cardiovascular disease (first of two parts). , 1981, The New England journal of medicine.

[18]  B. Stadel,et al.  Oral contraceptives and cardiovascular disease (second of two parts). , 1981, The New England journal of medicine.

[19]  G. Eklund,et al.  ORAL CONTRACEPTIVES AND THROMBOEMBOLIC DISEASE: EFFECTS OF LOWERING ŒSTROGEN CONTENT , 1980, The Lancet.

[20]  G. Eklund,et al.  Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. , 1980, Lancet.

[21]  M. Brozovīc,et al.  An Epidemiological Study of the Haemostatic and Other Effects of Oral Contraceptives , 1976, British journal of haematology.

[22]  W. Inman,et al.  Thromboembolic Disease and the Steroidal Content of Oral Contraceptives. A Report to the Committee on Safety of Drugs , 1970, British medical journal.

[23]  R. Doll,et al.  Investigation of Relation between Use of Oral Contraceptives and Thromboembolic Disease. A Further Report , 1969, British medical journal.

[24]  Clyne,et al.  Investigation of relation between use of oral contraceptives and thromboembolic disease. , 1968, British medical journal.